2,6-Difluoro-4-hydroxybenzenepropanoic Acid Ethyl Ester, can be used in the synthesis of potent and orally available agonists of G protein-coupled receptor 40 (GPR40), which has been found to be a new potential drug target for the treatment of type 2 diabetes.
